[Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies].

[1]  M. Rubin,et al.  The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2022, European urology.

[2]  Takayoshi Fuu,et al.  Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report , 2022, Journal of Medical Case Reports.

[3]  Jiaqiao Zhang,et al.  Impact of Treatment Modalities on Prognosis in Patients With Renal Collecting Duct Carcinoma: A Population-Based Study , 2022, Frontiers in Oncology.

[4]  L. Mariani,et al.  Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). , 2022, JAMA oncology.

[5]  S. Oudard,et al.  Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study , 2022, Cancers.

[6]  K. Gong,et al.  Collecting duct carcinoma of the kidney: Analysis of 74 cases from multiple centers. , 2022, Urology.

[7]  M. Yin,et al.  A rare curative case of collecting duct carcinoma , 2021, Urology case reports.

[8]  Xiaofang Zhang,et al.  Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review , 2021, Frontiers in Oncology.

[9]  Wenquan Zhou,et al.  Incidence, Clinical Characteristics, and Survival of Collecting Duct Carcinoma of the Kidney: A Population-Based Study , 2021, Frontiers in Oncology.

[10]  M. Matrana,et al.  Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series. , 2021, Clinical genitourinary cancer.

[11]  T. Danno,et al.  Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma , 2021, Case reports in urology.

[12]  V. Miller,et al.  Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. , 2021, Urologic oncology.

[13]  U. Capitanio,et al.  Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication , 2020, Cancers.

[14]  Y. Allory,et al.  724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial) , 2020 .

[15]  S. Chevret,et al.  Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study. , 2020 .

[16]  H. Miyake,et al.  Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney , 2019, International Cancer Conference Journal.

[17]  N. Tannir,et al.  Phase II trial of nivolumab (nivo) plus ipilimumab (ipi) in patients with SMARCB1-deficient kidney malignancies. , 2019, Journal of Clinical Oncology.

[18]  A. Maitra,et al.  p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. , 2019, Cancer cell.

[19]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Y. Nagashima,et al.  Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy , 2018, Medicine.

[21]  M. Di Maio,et al.  Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review , 2018, Clinical genitourinary cancer.

[22]  M. Atkins,et al.  Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma , 2018, Journal of Immunotherapy for Cancer.

[23]  P. Tamboli,et al.  Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study , 2017, BJU international.

[24]  T. Miyazaki,et al.  Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report , 2017, Molecular and clinical oncology.

[25]  A. Roychoudhury,et al.  Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database. , 2017, Urologic oncology.

[26]  P. Stephens,et al.  Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. , 2016, European urology.

[27]  N. Rioux-Leclercq,et al.  Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas , 2016, Scientific Reports.

[28]  T. Kuzel,et al.  Anti-programmed Death Receptor 1 Blockade Induces Clinical Response in a Patient With Metastatic Collecting Duct Carcinoma. , 2016, Clinical genitourinary cancer.

[29]  C. Tournigand,et al.  Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas. , 2016, European urology.

[30]  O. Alvarez,et al.  Renal medullary carcinoma and sickle cell trait: A systematic review , 2015, Pediatric blood & cancer.

[31]  C. Wetmore,et al.  Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. , 2015, Neuro-oncology.

[32]  A. Palazzo,et al.  Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[33]  G. Freeman,et al.  PD-L1 expression in nonclear-cell renal cell carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Hyo Song Kim,et al.  Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[35]  M. Colecchia,et al.  Treatment of collecting duct carcinoma: current status and future perspectives. , 2014, Anticancer research.

[36]  Y. Allory,et al.  Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Lars Egevad,et al.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia , 2013, The American journal of surgical pathology.

[38]  A. Kapoor,et al.  Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. , 2013, Current oncology.

[39]  I. Ostrovnaya,et al.  Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Lisa L. Smith,et al.  A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. , 2012, European urology.

[41]  M. Bronchud,et al.  HER2 Blockade in Metastatic Collecting Duct Carcinoma (CDC) of the Kidney: A Case Report , 2012, Oncology Research and Treatment.

[42]  T. Polascik,et al.  Characteristics and outcomes of tumors arising from the distal nephron. , 2012, Urology.

[43]  V. Gangireddy,et al.  Response of metastatic renal medullary carcinoma to carboplatinum and Paclitaxel chemotherapy. , 2012, Clinical genitourinary cancer.

[44]  P. Argani,et al.  Immunohistochemical analysis of SMARCB1/INI-1 expression in collecting duct carcinoma. , 2011, Urology.

[45]  Cynthia S. Johnson,et al.  Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  S. Oudard,et al.  [Bellini tumours]. , 2011, Bulletin du cancer.

[47]  L. Hilliard,et al.  Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma , 2010, Pediatric blood & cancer.

[48]  Ximing J. Yang,et al.  Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase‐inhibiting therapy , 2009, BJU international.

[49]  Ashesh B Jani,et al.  Influence of demographic factors on outcome of collecting duct carcinoma: a Surveillance, Epidemiology, and End Results (SEER) database analysis. , 2009, Clinical genitourinary cancer.

[50]  J. Epstein,et al.  Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy. , 2009, The Journal of urology.

[51]  N. Haseke,et al.  Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib. , 2008, European journal of medical research.

[52]  W. Rathmell,et al.  High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. , 2008, Urology.

[53]  O. Hes,et al.  Sunitinib in the treatment of tubulocystic carcinoma of the kidney. A case report. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  S. Culine,et al.  Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. , 2007, The Journal of urology.

[55]  M. Rouprêt,et al.  Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma? , 2003, The Journal of urology.

[56]  E. Perlman,et al.  Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. , 2002, Urology.

[57]  M. Atkins,et al.  Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. , 2001, Urology.

[58]  A. Amorosi,et al.  Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney. , 1997, The Journal of urology.